These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Schedules of controlled substances: temporary placement of 10 synthetic cathinones into Schedule I. Final order. Drug Enforcement Administration, Department of Justice Fed Regist; 2014 Mar; 79(45):12938-43. PubMed ID: 24611212 [TBL] [Abstract][Full Text] [Related]
43. Pill testing warrants assessment in careful pilot programmes. Komesaroff PA; Lloyd-Jones DM Intern Med J; 2019 Apr; 49(4):419-421. PubMed ID: 30957381 [No Abstract] [Full Text] [Related]
44. Seizures associated with synthetic cathinone exposures in the pediatric population. Tekulve K; Alexander A; Tormoehlen L Pediatr Neurol; 2014 Jul; 51(1):67-70. PubMed ID: 24814056 [TBL] [Abstract][Full Text] [Related]
45. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. Drug Enforcement Administration, Department of Justice Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903 [TBL] [Abstract][Full Text] [Related]
46. The consumable vice: caffeine, public health, and the law. Hodge JG; Scanlon M; Corbe A; Sorensen A J Contemp Health Law Policy; 2010; 27(1):76-119. PubMed ID: 21322400 [No Abstract] [Full Text] [Related]
47. A trip on "bath salts" is cheaper than meth or cocaine but much more dangerous. Slomski A JAMA; 2012 Dec; 308(23):2445-7. PubMed ID: 23288310 [No Abstract] [Full Text] [Related]
48. Irreversible motor impairment in young addicts--ephedrone, manganism or both? Sikk K; Taba P; Haldre S; Bergquist J; Nyholm D; Zjablov G; Asser T; Aquilonius SM Acta Neurol Scand; 2007 Jun; 115(6):385-9. PubMed ID: 17511846 [TBL] [Abstract][Full Text] [Related]
49. Constraints on regulatory options for putatively cognitive enhancing drugs. Hall W; Partridge B; Lucke J Am J Bioeth; 2013; 13(7):35-7. PubMed ID: 23767436 [No Abstract] [Full Text] [Related]
50. [Drugs and desperation in different worlds. Abuse of cathinone and methcathinone]. Aquilonius SM; Bergquist J; Dahllöf TA Lakartidningen; 2009 May 13-19; 106(20):1358-61. PubMed ID: 19585829 [No Abstract] [Full Text] [Related]
51. UK places generic ban on mephedrone drug family. Morris K Lancet; 2010 Apr; 375(9723):1333-4. PubMed ID: 20405534 [No Abstract] [Full Text] [Related]
52. Some first steps toward responsible use of cognitive-enhancing drugs by the healthy. Greely HT Am J Bioeth; 2013; 13(7):39-41. PubMed ID: 23767438 [No Abstract] [Full Text] [Related]
53. Beta-blocker use for toxicity from "bath salts". Richards JR; Laurin EG; Albertson TE J Emerg Med; 2015 Feb; 48(2):e45-6. PubMed ID: 25453853 [No Abstract] [Full Text] [Related]
54. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule. Drug Enforcement Administration, Department of Justice Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775 [TBL] [Abstract][Full Text] [Related]
55. Should drugs be decriminalised? No. Califano JA BMJ; 2007 Nov; 335(7627):967. PubMed ID: 17991977 [TBL] [Abstract][Full Text] [Related]
56. Establishment of drug codes for 26 substances. Final rule. Drug Enforcement Administration (DEA), Department of Justice Fed Regist; 2013 Jan; 78(3):664-6. PubMed ID: 23289157 [TBL] [Abstract][Full Text] [Related]
57. Should drugs be decriminalised? Yes. Chand K BMJ; 2007 Nov; 335(7627):966. PubMed ID: 17991976 [TBL] [Abstract][Full Text] [Related]
59. [Beta-cathinone derivatives--a new generation of dangerous psychostimulant "designer drugs"]. Zawilska JB; Słomiak K; Wasiak M; Woźniak P; Massalski M; Krupa E; Wojcieszak JŁ Przegl Lek; 2013; 70(6):386-91. PubMed ID: 24052975 [TBL] [Abstract][Full Text] [Related]
60. Enhancement policy and the value of information. Sandberg A Am J Bioeth; 2013; 13(7):34-5. PubMed ID: 23767435 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]